Eli Lilly and Company completed its acquisition of AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting therapies for mental health conditions.
The deal adds BPL-003, a lead investigational program for treatment-resistant depression, to Lilly’s neuroscience portfolio.
This acquisition reflects a broader industry trend of large pharmaceutical firms buying innovative companies to address significant unmet medical needs.